Literature DB >> 22863623

Vasculopathy related to cocaine adulterated with levamisole: A review of the literature.

Timothy Pearson1, Matthew Bremmer, Jared Cohen, Marcia Driscoll.   

Abstract

BACKGROUND: Recently, there have been numerous case reports and series describing patients presenting with cutaneous vasculopathy that has been linked to the levamisole frequently found in cocaine.
OBJECTIVE: The purpose of this study was to review all published case reports and series of patients reported with cutaneous vasculopathic findings of lemavisole induced vasculopathy (LIV) associated with cocaine use.
METHODS: A review of PubMed was performed searching the keywords: levamisole, cocaine, in combination with vasculitis, and vasculopathy. Twenty-two case reports and series were available with sufficient data on reported patients to be included. Four patients from the authors' clinical experience are included as well.
RESULTS: A number of common clinical and pathological findings are reviewed, including lower extremity (46/55 patients, 84%) and ear involvement (40/55 patients, 73%), and positive anti-neutrophil cytoplasmic antibodies (ANCA) findings (p-ANCA 42/48 patients, 88%; anti human neutrophil elastase 11/11 patients, 100%). Similar numbers of patients were treated with systemic corticosteroids as were treated conservatively; there was comparable improvement on follow up.
CONCLUSIONS: There are a number of clinical and laboratory findings that are commonly found in patients with LIV. There is currently insufficient data to recommend treatment with systemic corticosteroids in patients with this condition.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22863623

Source DB:  PubMed          Journal:  Dermatol Online J        ISSN: 1087-2108


  20 in total

1.  Levamisole-contaminated cocaine: a hairy affair.

Authors:  Tjeerd van der Veer; Ed Pennings; J W Cohen Tervaert; Lindy-Anne Korswagen
Journal:  BMJ Case Rep       Date:  2015-08-26

2.  Purple ear and retiform purpura.

Authors:  Zaw Min; Alireza Zarrabi; Abera Woldesenbet; Richard B Williams
Journal:  Intern Emerg Med       Date:  2013-11-28       Impact factor: 3.397

Review 3.  Cocaine-Levamisole-Induced Vasculitis/Vasculopathy Syndrome.

Authors:  Javier Marquez; Lina Aguirre; Carolina Muñoz; Andres Echeverri; Mauricio Restrepo; Luis F Pinto
Journal:  Curr Rheumatol Rep       Date:  2017-06       Impact factor: 4.592

Review 4.  Updates in ANCA-associated vasculitis.

Authors:  Christian Pagnoux
Journal:  Eur J Rheumatol       Date:  2016-01-29

5.  Levamisole Induced Pauci Immune Focal Necrotizing and Crescentic Glomerulonephritis.

Authors:  Randula Ranawaka; Manoji P Gamage; Kalpani Lokuge; David V Milford
Journal:  Indian J Pediatr       Date:  2018-01-02       Impact factor: 1.967

6.  Painful Violaceous Purpura on a 44-Year-Old Woman.

Authors:  Shirin Bajaj; Brian Hibler; Anthony Rossi
Journal:  Am J Med       Date:  2016-02-08       Impact factor: 4.965

7.  Photoletter to the editor: Diffuse cocaine-related purpura.

Authors:  Debjeet Sarkar; Hussein A Kammona; Leonard N Lamsen; Bradley A McAbee; Christopher T Clark; Solomon S Lee; Shane E Kelley
Journal:  J Dermatol Case Rep       Date:  2013-12-30

8.  Recurrent febrile neutropenia and thrombocytopenia in a chronic cocaine user: a case of levamisole induced complications.

Authors:  Eduardo Martinez; Raza Alvi; Sindhaghatta Venkatram; Gilda Diaz-Fuentes
Journal:  Case Rep Crit Care       Date:  2015-03-22

Review 9.  Is Levamisole-Induced Vasculitis a Relegated Diagnostic Possibility? A Case Report and Review of Literature.

Authors:  Soumya Patnaik; Percy Balderia; Lisa Vanchhawng; Peyman Markazi; Jedrzej Wykretowicz; Sarah Perloff
Journal:  Am J Case Rep       Date:  2015-09-25

10.  ANCA-positive vasculitis induced by levamisole-adulterated cocaine and nephrotic syndrome: The kidney as an unusual target.

Authors:  Hortensia Álvarez Díaz; Ana Isabel Marińo Callejo; José Francisco García Rodríguez; Laura Rodríguez Pazos; Inmaculada Gómez Buela; Ana María Bermejo Barrera
Journal:  Am J Case Rep       Date:  2013-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.